Avelumab and Merkel Cell Carcinoma Risk: What Studies Show

From General Health to Targeted Exposure Awareness

For decades, public health communication in the mass production sector has centered on general wellness principles—emphasizing hygiene, nutrition, and broad disease prevention. This foundational approach served workers well by establishing baseline health literacy and encouraging routine medical engagement. However, as industrial environments evolve with novel therapeutic agents entering occupational settings, the traditional general-health lens proves insufficient for addressing emerging, substance-specific risks. The shift from generic health promotion to targeted exposure awareness becomes necessary when production processes involve pharmaceutical compounds. Avelumab, a monoclonal antibody used in oncology, exemplifies this transition. While originally developed for clinical treatment, its presence in manufacturing, handling, or disposal contexts introduces a distinct occupational dimension. Workers may encounter this agent through inhalation, dermal contact, or accidental ingestion, raising legitimate questions about long-term health consequences beyond immediate toxicity. This pivot does not imply alarm but rather a refined focus: from “staying healthy in general” to understanding how specific chemical exposures—such as avelumab—might correlate with rare outcomes like Merkel cell carcinoma. The occupational health paradigm must therefore integrate pharmacovigilance principles, monitoring not just acute effects but also delayed, low-incidence risks. By bridging general health heritage with targeted exposure inquiry, we can develop evidence-based protocols that protect workers without overstating unproven causal links. This transition respects the legacy of broad health education while acknowledging the precision required for modern industrial toxicology.

Avelumab: Mechanism and Therapeutic Role

Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It has been approved in the United States, the European Union, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with a poor prognosis (https://pubmed.ncbi.nlm.nih.gov/29799096/). The approval was based on the two-part, single-arm, phase II JAVELIN Merkel 200 trial, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096/). This makes avelumab the first therapeutic agent specifically approved for this indication, and it is approved for use independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/).

Merkel Cell Carcinoma: Etiology and Epidemiology

Merkel cell carcinoma is associated with chronic exposure to ultraviolet light and the Merkel cell polyomavirus, with approximately 80% of cases caused by the virus and the remaining 20% induced by UV light leading to mutations (https://pubmed.ncbi.nlm.nih.gov/35877101/; https://pubmed.ncbi.nlm.nih.gov/34445385/). The incidence of MCC is rising, and the disease is associated with high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/). Immune checkpoint inhibitors, including avelumab and pembrolizumab, offer durable responses and significant clinical benefit, with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/). However, approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). Additionally, 50% of patients do not respond or develop immune-related adverse events due to diverse mechanisms, such as down-regulation of MHC complexes or the induction of anti-inflammatory cytokines (https://pubmed.ncbi.nlm.nih.gov/34445385/).

Evidence on Avelumab and MCC Risk

The mechanistic pathway linking avelumab to MCC risk is primarily through its role as an immune checkpoint inhibitor. By blocking PD-L1, avelumab enhances T-cell responses against tumor cells, which is the intended therapeutic effect (https://pubmed.ncbi.nlm.nih.gov/34445385/). However, this immune activation can also lead to immune-related adverse events, which may include the development or progression of MCC in some patients. The timeline between avelumab exposure and documented harm varies, as responses and adverse events can occur during treatment or after discontinuation. The JAVELIN Merkel 200 trial and subsequent studies have documented both objective responses and progression in patients treated with avelumab, with approximately 50% of patients not responding or progressing on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/; https://pubmed.ncbi.nlm.nih.gov/34445385/). Regarding the adequacy of warnings, the approved labeling for avelumab includes information about immune-related adverse events, but specific warnings about MCC risk are not explicitly detailed in the available evidence. The risk of progression or lack of response is inherent to the disease and treatment, and the evidence indicates that avelumab is approved for MCC treatment, not as a cause of MCC. Causation considerations for affected patients focus on the natural history of MCC and the therapeutic context, where avelumab is used to treat existing disease rather than induce it. The timeline between exposure and harm is typically measured in weeks to months during treatment, as seen in clinical trials where responses and progression are assessed at regular intervals.

Clinical Outcomes and Alternative Therapies

For patients who are refractory to avelumab, efficient and safe treatment options are lacking (https://pubmed.ncbi.nlm.nih.gov/33439294/). In a multicenter study of the prospective skin cancer registry ADOREG, ipilimumab plus nivolumab was evaluated in avelumab-refractory MCC patients (https://pubmed.ncbi.nlm.nih.gov/36450381/). Similarly, a retrospective study of ipilimumab plus nivolumab in anti-PD-L1/PD-1 refractory MCC was conducted (https://pubmed.ncbi.nlm.nih.gov/35877101/). In a separate report, five patients treated at three different academic sites in Germany were enrolled, and three out of five patients responded to combined ipilimumab plus nivolumab according to RECIST 1.1 (https://pubmed.ncbi.nlm.nih.gov/33439294/). These findings indicate that while avelumab is a standard treatment for metastatic MCC, a significant proportion of patients do not achieve durable responses and may require alternative therapies.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

Can avelumab cause Merkel cell carcinoma?

Current evidence does not support a causal link between avelumab and the development of Merkel cell carcinoma. Avelumab is an immune checkpoint inhibitor approved for treating metastatic MCC, and its intended effect is to enhance T-cell responses against tumor cells. While some patients may experience progression or lack of response, this is considered part of the natural history of the disease rather than a direct causal effect of the drug. (https://pubmed.ncbi.nlm.nih.gov/29799096/)

What is the risk of developing MCC after avelumab exposure?

The risk of developing MCC after avelumab exposure is not established. Avelumab is used to treat existing MCC, and studies have not shown that it induces new cases of MCC. The primary risks associated with avelumab are immune-related adverse events and potential lack of therapeutic response. (https://pubmed.ncbi.nlm.nih.gov/34445385/)

What should I do if I have been exposed to avelumab and diagnosed with MCC?

If you have documented avelumab exposure and a confirmed MCC diagnosis, you may request an independent eligibility review through the Information Registry. It is important to consult with a healthcare provider to discuss your individual case and potential treatment options, including alternative immune checkpoint inhibitor combinations. (https://pubmed.ncbi.nlm.nih.gov/33439294/)

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel Cell Carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.